BLTE Belite Bio Inc ADR

USD 49.16 0.00 0
Icon

Belite Bio Inc ADR (BLTE) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 49.16

0.00 (0.00)%

USD 1.37B

0.02M

USD 58.50(+19.00%)

N/A

Icon

BLTE

Belite Bio Inc ADR (USD)
COMMON STOCK | NSD
USD 49.16
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 1.37B

N/A

USD 49.16

Belite Bio Inc ADR (BLTE) Stock Forecast

Show ratings and price targets of :
USD 58.50
(+19.00%)

Based on the Belite Bio Inc ADR stock forecast from 2 analysts, the average analyst target price for Belite Bio Inc ADR is USD 58.50 over the next 12 months. Belite Bio Inc ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Belite Bio Inc ADR is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Belite Bio Inc ADR’s stock price was USD 49.16. Belite Bio Inc ADR’s stock price has changed by +8.04% over the past week, -1.88% over the past month and +279.91% over the last year.

No recent analyst target price found for Belite Bio Inc ADR
No recent average analyst rating found for Belite Bio Inc ADR

Company Overview Belite Bio Inc ADR

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (...Read More

https://www.belitebio.com

12750 High Bluff Drive, San Diego, CA, United States, 92130

20

December

USD

USA

Adjusted Closing Price for Belite Bio Inc ADR (BLTE)

Loading...

Unadjusted Closing Price for Belite Bio Inc ADR (BLTE)

Loading...

Share Trading Volume for Belite Bio Inc ADR Shares

Loading...

Compare Performance of Belite Bio Inc ADR Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BLTE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Belite Bio Inc ADR (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD127.00B 31.94 20.00

ETFs Containing BLTE

Symbol Name BLTE's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Belite Bio Inc ADR (BLTE) Stock

Based on ratings from 2 analysts Belite Bio Inc ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and hold ratings.

Unfortunately we do not have enough data on BLTE's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for BLTE is USD 58.50 over the next 12 months. The maximum analyst target price is USD 59 while the minimum anlayst target price is USD 57.

Unfortunately we do not have enough data on BLTE's stock to indicate if its overvalued.

The last closing price of BLTE's stock was USD 49.16.

The most recent market capitalization for BLTE is USD 1.37B.

Based on targets from 2 analysts, the average taret price for BLTE is projected at USD 58.50 over the next 12 months. This means that BLTE's stock price may go up by +19.00% over the next 12 months.

We can't find any ETFs which contains Belite Bio Inc ADR's stock.

As per our most recent records Belite Bio Inc ADR has 20 Employees.

Belite Bio Inc ADR's registered address is 12750 High Bluff Drive, San Diego, CA, United States, 92130. You can get more information about it from Belite Bio Inc ADR's website at https://www.belitebio.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...